Patents by Inventor Michael E. Kort

Michael E. Kort has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Degrader Compounds and Uses Thereof
    Publication number: 20240424111
    Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: June 21, 2022
    Publication date: December 26, 2024
    Inventors: Gesine Kerstin VEITS, Mark E. FITZGERALD, Alexander W. HIRD, Ramzi F. SWEIS, Michael E. KORT
  • Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
    Publication number: 20240383886
    Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: November 21, 2024
    Inventors: Gesine Kerstin Veits, Mark E. Fitzgerald, Alexander W. Hird, James A. Henderson, Harit U. Vora, Ramzi F. Sweis, Michael E. Kort, Christopher G. Nasveschuk, Martin Duplessis
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20230066771
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 2, 2023
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20210130293
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: October 16, 2019
    Publication date: May 6, 2021
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20190055196
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: August 22, 2018
    Publication date: February 21, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20180334435
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 13, 2018
    Publication date: November 22, 2018
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Nuclear receptor modulators
    Patent number: 10106501
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 23, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9969693
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 15, 2018
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • TRPA1 antagonists
    Patent number: 9751850
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: September 5, 2017
    Assignee: ABBVIE INC.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20170226062
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: August 17, 2016
    Publication date: August 10, 2017
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20160362370
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 15, 2016
    Applicant: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20160355482
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 8, 2016
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9452986
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 27, 2016
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • TRPV3 modulators
    Patent number: 9156788
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 13, 2015
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Eric A. Voight
  • TRPA1 antagonists
    Patent number: 9108905
    Abstract: Compounds of formula (I) wherein R1, R2, R3, m, and Y are defined in the specification are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: August 18, 2015
    Assignee: AbbVie Inc.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jr., Jun Chen, Anil Vasudevan
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20150218102
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • TRPV3 modulators
    Patent number: 9012651
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein X1, X2, R1, R2, Rx, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 21, 2015
    Assignee: AbbVie Inc.
    Inventors: Bruce Clapham, Phil B. Cox, Michael J. Dart, Arthur Gomtsyan, Tammie K. Jinkerson, Ryan G. Keddy, Michael E. Kort, Philip R. Kym, Mark Matulenko, Robert G. Schmidt, Clara I. Villamil, Eric A. Voight, Kevin R. Woller
  • TRPA1 ANTAGONISTS
    Publication number: 20150065538
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: November 4, 2014
    Publication date: March 5, 2015
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • TRPV1 antagonists
    Patent number: 8969325
    Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: March 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Michael J. Dart, Philip R. Kym, Eric A. Voight, Anurupa Shrestha, Jerome F. Daanen, Tammie K. Jinkerson, Ryan G. Keddy, Sridhar Peddi, Arthur Gomtsyan, Michael E. Kort, Gregory A. Gfesser, Kevin R. Woller, Derek W. Nelson
  • TRPA1 antagonists
    Patent number: 8877784
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan